SZodixStudyAcademic Library
ShelvesOpen access
Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated
Economic evaluation of a randomized clinical trial comparing vinorelbine, vinorelbine plus cisplatin, and vindesine plus cisplatin for non-small-cell lung cancer.
4 references·4 citing·30 second hop
Economic evaluation of a randomized clinical trial comparing vinorelbine, vinorelbine plus cisplatin, and vindesine plus cisplatin for non-small-cell lung cancer. (1995)Economic evaluation of a randomized clini…How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. (1992)How attractive does a new tec…Efficacy and Cost-effectiveness of Autologous Bone Marrow Transplantation in Metastatic Breast Cancer (1992)Efficacy and Cost-effectivene…Efficacy and Cost Effectiveness of Adjuvant Chemotherapy in Women with Node-Negative Breast Cancer (1991)Efficacy and Cost Effectivene…Cost Effectiveness of Prophylactic Intravenous Immune Globulin in Chronic Lymphocytic Leukemia (1991)Cost Effectiveness of Prophyl…A Review and Meta-Analysis of Utility Values for Lung Cancer (2010)A Review and Meta-Analysis of…Economic Analysis of Vinorelbine Plus Cisplatin Versus Paclitaxel Plus Carboplatin for Advanced Non-Small-Cell Lung Cancer (2002)Economic Analysis of Vinorelb…Economic Analysis of the TAX 317 Trial: Docetaxel Versus Best Supportive Care as Second-Line Therapy of Advanced Non-Small-Cell Lung Cancer (2002)Economic Analysis of the TAX …Economic issues in lung cancer: a review. (1998)Economic issues in lung cance…Counting the costs of chemotherapy in a National Cancer Institute of Canada randomized trial in nonsmall-cell lung cancer. (1990)Methods for the Economic Evaluation of Health Care Programmes (2005)The Top 100 Most Frequently Cited Publications Concerning Anti-PD-1/PD-L1 Therapy for Lung Cancer: A Bibliometric Analysis (2021)A methodological framework for assessing health indices (1985)Measurement of health state utilities for economic appraisal (1986)Meta-Analyses of Randomized Controlled Trials (1987)Costs, effects and C/E‐ratios alongside a clinical trial (1994)A study of the quality of life and cost-utility of renal transplantation (1996)Multiattribute Utility Function for a Comprehensive Health Status Classification System (1996)The Markov Process in Medical Prognosis (1983)A Clinician's Guide to Cost-Effectiveness Analysis (1990)Setting Health Care Priorities in Oregon (1991)Cost-effectiveness of captopril therapy after myocardial infarction (1995)Sensitivity analysis in economic evaluation: A review of published studies (1995)A Cost-Effectiveness Analysis of Adjuvant Trastuzumab Regimens in Early HER2/neu–Positive Breast Cancer (2007)Optimistic Biases About Personal Risks (1989)Assessment of quality of life in clinical trials (1991)Cost-utility in practice: A policy maker's guide to the state of the art (1992)HER-2 Testing and Trastuzumab Therapy for Metastatic Breast Cancer: A Cost-Effectiveness Analysis (2004)Clinical decision analysis (2005)The utility of different health states as perceived by the general public (1978)Whose Utilities for Decision Analysis? (1990)Meta-Analysis, Decision Analysis, and Cost-Effectiveness Analysis: Methods for Quantitative Synthesis in Medicine (1994)Cost-utility analysis of a potential lung cancer screening program for a high-risk population in Germany: A modelling approach (2018)Economic Analysis Alongside Clinical Trials: Revisiting the Methodological Issues (1991)The Journal's Policy on Cost-Effectiveness Analyses (1994)The Burden of Illness of Cancer: Economic Cost and Quality of Life (2001)The standard gamble method: what is being measured and how it is interpreted. (1994)EVALUATING THE COST-EFFECTIVENESS OF CLINICAL AND PUBLIC HEALTH MEASURES (1998)Cost-effectiveness of omalizumab in adults with severe asthma: Results from the Asthma Policy Model (2007)
this work references cited by second hop

References

  • 1992How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations.1,581 cited
  • 1991Efficacy and Cost Effectiveness of Adjuvant Chemotherapy in Women with Node-Negative Breast Cancer237 cited
  • 1991Cost Effectiveness of Prophylactic Intravenous Immune Globulin in Chronic Lymphocytic Leukemia204 cited
  • 1992Efficacy and Cost-effectiveness of Autologous Bone Marrow Transplantation in Metastatic Breast Cancer139 cited

Cited by

  • 2010A Review and Meta-Analysis of Utility Values for Lung Cancer78 cited
  • 2002Economic Analysis of Vinorelbine Plus Cisplatin Versus Paclitaxel Plus Carboplatin for Advanced Non-Small-Cell Lung Cancer74 cited
  • 2002Economic Analysis of the TAX 317 Trial: Docetaxel Versus Best Supportive Care as Second-Line Therapy of Advanced Non-Small-Cell Lung Cancer71 cited
  • 1998Economic issues in lung cancer: a review.70 cited

Only edges whose both ends are imported exist here. Widen the year window, or show the whole map. Back to the work